Zacks Research Expects Increased Earnings for Haemonetics

Haemonetics Co. (NYSE:HAE) – Equities researchers at Zacks Research raised their FY2026 earnings per share estimates for Haemonetics in a research note issued on Monday, December 9th. Zacks Research analyst R. Department now forecasts that the medical instruments supplier will post earnings per share of $5.18 for the year, up from their previous estimate of $5.17. The consensus estimate for Haemonetics’ current full-year earnings is $4.59 per share.

A number of other research firms have also recently commented on HAE. Raymond James upgraded Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price objective on the stock in a report on Friday, November 8th. Citigroup decreased their price target on Haemonetics from $94.00 to $85.00 and set a “neutral” rating on the stock in a research note on Thursday, August 22nd. CL King initiated coverage on Haemonetics in a report on Friday, September 13th. They set a “buy” rating and a $116.00 price target for the company. BTIG Research started coverage on shares of Haemonetics in a report on Tuesday, September 10th. They issued a “buy” rating and a $112.00 price objective on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $112.00 target price on shares of Haemonetics in a research note on Tuesday, December 3rd. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $108.78.

Haemonetics Stock Performance

NYSE:HAE opened at $83.34 on Wednesday. The company’s 50-day moving average is $80.83 and its two-hundred day moving average is $81.62. Haemonetics has a 1-year low of $70.25 and a 1-year high of $97.97. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.49 and a quick ratio of 2.09. The firm has a market capitalization of $4.19 billion, a price-to-earnings ratio of 34.58, a PEG ratio of 1.26 and a beta of 0.38.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.09 by $0.03. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. The company had revenue of $345.50 million during the quarter, compared to analysts’ expectations of $342.57 million. During the same period in the prior year, the business earned $0.99 EPS. The firm’s quarterly revenue was up 8.6% on a year-over-year basis.

Institutional Investors Weigh In On Haemonetics

A number of hedge funds have recently added to or reduced their stakes in HAE. Geode Capital Management LLC grew its stake in Haemonetics by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,193,927 shares of the medical instruments supplier’s stock worth $95,986,000 after purchasing an additional 21,547 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new position in shares of Haemonetics during the third quarter worth about $382,000. XTX Topco Ltd grew its position in shares of Haemonetics by 84.9% during the third quarter. XTX Topco Ltd now owns 8,450 shares of the medical instruments supplier’s stock worth $679,000 after buying an additional 3,880 shares in the last quarter. Zacks Investment Management increased its stake in shares of Haemonetics by 11.5% during the third quarter. Zacks Investment Management now owns 16,921 shares of the medical instruments supplier’s stock worth $1,360,000 after buying an additional 1,740 shares during the period. Finally, iSAM Funds UK Ltd acquired a new stake in Haemonetics in the third quarter valued at approximately $204,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.